Literature DB >> 31672763

Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ.

Natividad Gomez-Roman1, Ming Y Chong2, Sandeep K Chahal2, Seamus P Caragher2, Mark R Jackson2, Katrina H Stevenson2, Sidhartha A Dongre2, Anthony J Chalmers2.   

Abstract

Glioblastoma is resistant to conventional treatments and has dismal prognosis. Despite promising in vitro data, molecular targeted agents have failed to improve outcomes in patients, indicating that conventional two-dimensional (2D) in vitro models of GBM do not recapitulate the clinical scenario. Responses of primary glioblastoma stem-like cells (GSC) to radiation in combination with EGFR, VEGF, and Akt inhibition were investigated in conventional 2D cultures and a three-dimensional (3D) in vitro model of GBM that recapitulates key GBM clinical features. VEGF deprivation had no effect on radiation responses of 2D GSCs, but enhanced radiosensitivity of GSC cultures in 3D. The opposite effects were observed for EGFR inhibition. Detailed analysis of VEGF and EGF signaling demonstrated a radioprotective role of Akt that correlates with VEGF in 3D and with EGFR in 2D. In all cases, positive correlations were observed between increased radiosensitivity, markers of unrepaired DNA damage and persistent phospho-DNA-PK nuclear foci. Conversely, increased numbers of Rad51 foci were observed in radioresistant populations, indicating a novel role for VEGF/Akt signaling in influencing radiosensitivity by regulating the balance between nonhomologous end-joining and homologous recombination-mediated DNA repair. Differential activation of tyrosine kinase receptors in 2D and 3D models of GBM explains the well documented discrepancy between preclinical and clinical effects of EGFR inhibitors. Data obtained from our 3D model identify novel determinants and mechanisms of DNA repair and radiosensitivity in GBM, and confirm Akt as a promising therapeutic target in this cancer of unmet need. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31672763     DOI: 10.1158/1535-7163.MCT-18-1320

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  7 in total

Review 1.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

Review 2.  DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.

Authors:  Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Paul A Tooney
Journal:  Cell Oncol (Dordr)       Date:  2021-05-31       Impact factor: 6.730

Review 3.  PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

Authors:  Elizabeth K Lee; Ursula A Matulonis
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

4.  Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.

Authors:  Ge Zhang; Xiang Tao; Baowei Ji; Jie Gong
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

5.  Comparison of VEGF-A secretion from tumor cells under cellular stresses in conventional monolayer culture and microfluidic three-dimensional spheroid models.

Authors:  Sreerupa Sarkar; Chien-Chung Peng; Yi-Chung Tung
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

Review 6.  DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.

Authors:  Ola Rominiyi; Spencer J Collis
Journal:  Mol Oncol       Date:  2021-06-11       Impact factor: 6.603

7.  Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.

Authors:  Chiara Liverani; Alessandro De Vita; Chiara Spadazzi; Giacomo Miserocchi; Claudia Cocchi; Alberto Bongiovanni; Anna De Lucia; Federico La Manna; Francesco Fabbri; Michela Tebaldi; Dino Amadori; Ennio Tasciotti; Giovanni Martinelli; Laura Mercatali; Toni Ibrahim
Journal:  Mol Oncol       Date:  2021-07-10       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.